ModraDoc001

ModraDoc001 is a novel oral formulation of docetaxel that was developed as a solid dispersion with polyvinylpyrrolidone-K30 and sodium lauryl sulphate to increase its oral bioavailability[6]. Traditional docetaxel has poor oral bioavailability, but ModraDoc001 addresses this limitation through its specialized formulation[1][8].\n\nThe drug is administered in combination with ritonavir, which serves as an inhibitor of CYP3A4 and P-glycoprotein, further enhancing docetaxel's bioavailability by reducing its metabolism in the liver and gut wall[1][6].\n\n## Clinical Development\n\nModraDoc001 has been evaluated in Phase I clinical trials for patients with advanced solid tumors. In these trials, it was administered as a capsule (10 mg) in combination with ritonavir (100-200 mg) in a once-weekly continuous schedule[1][8].\n\nThe recommended Phase II dose (RP2D) was determined to be 60 mg ModraDoc001 with 100 mg ritonavir[1][8]. At this dosage, the area under the plasma concentration-time curve (AUC0-48) of docetaxel was 1,000 ± 687 ng/mL/hour[1][8].\n\n## Safety Profile\n\nThe most common adverse events associated with ModraDoc001 treatment were:\n- Nausea\n- Vomiting\n- Diarrhea\n- Fatigue\n\nMost of these toxicities were grade 1-2 in severity[1][8]. Notably, no hypersensitivity reactions were observed, which is a common concern with intravenous docetaxel administration[1].\n\nDose-limiting toxicities observed in clinical trials included grade 3 diarrhea, elevated liver enzymes (ASAT/ALAT), grade 4 dehydration, grade 3 mucositis, and grade 3 fatigue[6].\n\n## Efficacy\n\nIn Phase I trials, ModraDoc001 showed promising antitumor activity. Nine partial responses were reported as the best response to treatment across the studies[1][8]. Additionally, 15 patients achieved sustained stable disease[6].\n\nPartial responses were observed in patients with various cancer types, including carcinoma of unknown primary, non-small-cell lung cancer, gastric cancer, and breast cancer[6].\n\n## Development Status\n\nModraDoc001 has been studied alongside other formulations like ModraDoc006 (tablet form) by Modra Pharmaceuticals. As of July 2024, the drug was in Phase II development for breast cancer, prostate cancer, and solid tumors[3].\n\nThe development of ModraDoc001 represents an important advancement in taxane therapy, potentially offering patients a more convenient oral alternative to traditional intravenous docetaxel administration while maintaining efficacy and potentially improving the side effect profile.